Drug Elevating Efficiency: Validated RP-HPLC Method for Concurrent Detection of Cabotegravir and Rilpivirine in Medicine
Author(s): Kiran Kumar Ganta and Raja Sundararajan*
Abstract
Background: Type I HIV can be treated by the combination of these drugs. A novel, precise, and accurate RP-HPLC technique was developed and validated for concurrent assessment of cabotegravir and rilpivirine in pure and medicinal dose form.
Materials and methods: The analyte separation was achieved by Waters 2695 HPLC system that comprised of quaternary pumps and photodiode array detector. Mobile phase was in the ratio of (70:30 v/v) acetonitrile and 0.1N potassium di hydrogen phosphate. Flow rate of 1 ml/min was employed. The detector wavelength was at 257 nm. The run time was 5 min.
Results: The regression equation for cabotegravir was found to be y=7596.9x+1542.1 and for rilpivirine it was y=7517.8x+5409. LOD values for cabotegravir and rilpivirine were observed to be 0.25 μg/ml and 1.79 μg/ml respectively. LOQ values for cabotegravir and rilpivirine were found to be 0.77 μg/ml and 5.44 μg/ml respectively.
Conclusion: The proposed method was shown to be exact, accurate, and perfect for usage in QC labs for quantitative analysis of pharmaceutical dosage forms, both single and combined.
